Seeking Innovative Ophthalmology Drug Projects, Considering Small Molecules, Monoclonal/Polyclonal Antibodies, Nucleic Acid Drugs, Molecular Glues, Gene Therapies…

Driven by the rising prevalence of eye diseases and increased public awareness of healthcare, the market demand for the diagnosis and treatment of ocular conditions has surged. According to Fortune Business Insights, the global ophthalmic disease treatment market is projected to grow from $37.74 billion in 2024 to $52.67 billion by 2032, with a compound annual growth rate (CAGR) of 6.5% during this period.

In terms of specific ophthalmic diseases, refractive errors and cataracts have the highest prevalence. Additionally, with the intensification of population aging, the market size for retinal diseases is also experiencing rapid growth. A report by Eggshell Research Institute indicates that macular degeneration is one of the world’s top three blinding diseases and a serious yet often overlooked retinal condition among middle-aged and elderly populations. In China, the incidence of macular degeneration is approximately 10.6% in people aged 60 and above.

From a business development (BD) transaction perspective, ophthalmology has emerged as a high-potential field of interest, alongside autoimmune diseases, oncology, and central nervous system (CNS) disorders, amid the current BD boom. In mid-2024, Merck & Co. acquired EyeBio, a company focused on ophthalmology, for up to $3 billion. Earlier, companies like Johnson & Johnson, AbbVie, Amgen, and Astellas had also rapidly entered the field through acquisitions or pipeline transactions.

The BD team at Yaoshidai, commissioned by European and American pharmaceutical companies, is urgently seeking ophthalmology projects with the following specifications:

1. Project Stage: PCC ~ Phase 2 ongoing;
2. Molecule Types: Small molecules (eye drops), PROTAC, molecular glues, siRNA, ASO, gene therapy, multi-/monoclonal antibodies (for monoclonal antibodies, novel targets are preferred);
3. Indications: Age-related macular degeneration (AMD, dry or wet), glaucoma, diabetic retinopathy, diabetic macular edema, thyroid eye disease (TED), Stargardt disease.

The clients have no restrictions on the route of administration but prefer eye drops and assets with standalone efficacy.

If you have projects that meet the above criteria, please contact the Yaoshidai BD team immediately and include the specific project code in your email (Project Code: DTD-031).

Contact us:
For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!